Stockreport

Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout [Seeking Alpha]

Genmab A/S - American Depositary Shares  (GMAB) 
PDF Ficera's Phase 1b results in HPV-negative HNSCC show strong efficacy, outperforming current standards, albeit rival Merus' petosemtamab data is arguably stronger. BCA [Read more]